Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

Autor: Hironaga Satake, Nobuhiro Shibata, Mototsugu Shimokawa, T. Ikoma, Hiroki Nagai, Shogen Boku, Hisateru Yasui, Toshihiko Matsumoto, Masahito Kotaka
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Neuroblastoma RAS viral oncogene homolog
Oncology
Cancer Research
endocrine system diseases
Colorectal cancer
Mutant
medicine.disease_cause
GTP Phosphohydrolases
0302 clinical medicine
Surgical oncology
Medicine
RC254-282
Aged
80 and over
Hazard ratio
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
Prognosis
030220 oncology & carcinogenesis
Female
KRAS
KRAS non-Exon2
Colorectal Neoplasms
Adult
Proto-Oncogene Proteins B-raf
medicine.medical_specialty
Adolescent
NRAS
Proto-Oncogene Proteins p21(ras)
Young Adult
03 medical and health sciences
Internal medicine
Genetics
Overall survival
Humans
neoplasms
KRAS Exon2
Aged
business.industry
Research
Membrane Proteins
medicine.disease
digestive system diseases
030104 developmental biology
Multicenter study
Mutation
business
Zdroj: BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
ISSN: 1471-2407
Popis: Background RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant metastatic CRC (mCRC) in Japan. Methods A total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS/BRAFV600E status was investigated. RAS/BRAFV600E status was examined using a MEBGEN RASKET-B kit and polymerase chain reaction reverse sequence-specific oligonucleotide method. Results RAS/BRAFV600E mutations were detected in 54% of cases (KRAS codon 12, 26%; KRAS codon 13, 17%; KRAS non-Exon2, 5%; NRAS, 5%; and BRAFV600E, 7%). BRAFV600E-mutant CRC mainly existed in the right colon, whereas KRAS non-Exon2 and NRAS-mutant CRC was predominantly present in the left colon. KRAS non-Exon2 and NRAS-mutant CRC were associated with shorter survival time than RAS wild-type CRC (hazard ratio [HR], 2.26; 95% confidence interval [CI], 0.64–8.03; p = 0.19; HR, 2.42; 95% CI, 0.68–8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92–16.3; p = 0.04; HR, 4.80; 95% CI, 1.14–20.2; p = 0.02). Conclusions In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant mCRC in Japan.
Databáze: OpenAIRE
Externí odkaz: